Protara Therapeutics (TARA) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $2.40, -3.23% vs the prior close of $2.48.
- Volume 861.70K shares, 0.9x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
TARA slides 3.2% to $2.40, a 52-week low, 3 down days in a row. Closed at $2.40, -3.23% vs the prior close of $2.48. Day range $2.38–$2.56, opened at $2.51.
TARA daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — TARA slides 3.2% to $2.40, a 52-week low, 3 down days in a row
- Closed at $2.40, -3.23% vs the prior close of $2.48. Day range $2.38–$2.56, opened at $2.51.
- Volume was 861.70K shares, 0.9x its 50-day average of 965.91K.
- Price is -32.0% vs its 50-day average ($3.53) and -49.2% vs its 200-day average ($4.72).
- 52-week range $2.38–$7.82; today's close sits at 0% of that range, 69.3% below the 52-week high.
- That makes 3 straight losses.
Oct 14, 2026 — TARA slides 5.3% to $2.48, a 52-week low
- Closed at $2.48, -5.34% vs the prior close of $2.62. Day range $2.47–$2.66, opened at $2.60.
- Volume was 701.40K shares, 0.7x its 50-day average of 960.39K.
- Price is -30.4% vs its 50-day average ($3.56) and -47.7% vs its 200-day average ($4.74).
- 52-week range $2.47–$7.82; today's close sits at 0% of that range, 68.3% below the 52-week high.
Oct 13, 2026 — TARA slides 5.4% to $2.62
- Closed at $2.62, -5.42% vs the prior close of $2.77. Day range $2.62–$2.83, opened at $2.77.
- Volume was 930.20K shares, 1.0x its 50-day average of 946.62K.
- Price is -27.1% vs its 50-day average ($3.59) and -44.9% vs its 200-day average ($4.75).
- 52-week range $2.51–$7.82; today's close sits at 2% of that range, 66.5% below the 52-week high.
Oct 12, 2026 — TARA rises 0.5% to $2.77, 4 up days in a row
- Closed at $2.77, +0.54% vs the prior close of $2.76. Day range $2.70–$2.79, opened at $2.75.
- Volume was 1.08M shares, 1.2x its 50-day average of 930.90K.
- Price is -23.5% vs its 50-day average ($3.62) and -41.9% vs its 200-day average ($4.77).
- 52-week range $2.51–$7.82; today's close sits at 5% of that range, 64.6% below the 52-week high.
- That makes 4 straight gains.
Oct 9, 2026 — TARA jumps 4.0% to $2.76, 3 up days in a row
- Closed at $2.76, +3.96% vs the prior close of $2.65. Day range $2.65–$2.79, opened at $2.69.
- Volume was 1.04M shares, 1.1x its 50-day average of 915.62K.
- Price is -24.4% vs its 50-day average ($3.64) and -42.4% vs its 200-day average ($4.78).
- 52-week range $2.51–$7.82; today's close sits at 5% of that range, 64.8% below the 52-week high.
- That makes 3 straight gains.
Oct 8, 2026 — TARA rises 2.3% to $2.65
- Closed at $2.65, +2.32% vs the prior close of $2.59. Day range $2.52–$2.69, opened at $2.59.
- Volume was 1.22M shares, 1.3x its 50-day average of 904.36K.
- Price is -27.8% vs its 50-day average ($3.67) and -44.7% vs its 200-day average ($4.79).
- 52-week range $2.51–$7.82; today's close sits at 3% of that range, 66.1% below the 52-week high.
Oct 7, 2026 — TARA rises 1.4% to $2.59
- Closed at $2.59, +1.37% vs the prior close of $2.56. Day range $2.51–$2.67, opened at $2.54.
- Volume was 731.30K shares, 0.8x its 50-day average of 897.17K.
- Price is -29.8% vs its 50-day average ($3.69) and -46.1% vs its 200-day average ($4.81).
- 52-week range $2.51–$7.82; today's close sits at 2% of that range, 66.9% below the 52-week high.
Oct 6, 2026 — TARA dips 2.9% to $2.56, a 52-week low, 10 down days in a row
- Closed at $2.56, -2.85% vs the prior close of $2.63. Day range $2.53–$2.70, opened at $2.63.
- Volume was 803.50K shares, 0.9x its 50-day average of 891.77K.
- Price is -31.3% vs its 50-day average ($3.72) and -47.0% vs its 200-day average ($4.82).
- 52-week range $2.53–$7.82; today's close sits at 0% of that range, 67.3% below the 52-week high.
- That makes 10 straight losses.
Oct 5, 2026 — TARA dips 2.6% to $2.63, a 52-week low, 9 down days in a row
- Closed at $2.63, -2.59% vs the prior close of $2.70. Day range $2.57–$2.72, opened at $2.71.
- Volume was 1.40M shares, 1.6x its 50-day average of 872.51K.
- Price is -29.8% vs its 50-day average ($3.75) and -45.6% vs its 200-day average ($4.83).
- 52-week range $2.57–$7.82; today's close sits at 1% of that range, 66.4% below the 52-week high.
- That makes 9 straight losses.
Oct 2, 2026 — TARA dips 2.2% to $2.70, a 52-week low on 2.3x normal volume
- Closed at $2.70, -2.17% vs the prior close of $2.76. Day range $2.62–$2.95, opened at $2.81.
- Volume was 1.91M shares, 2.3x its 50-day average of 842.29K — unusually heavy trading.
- Price is -28.5% vs its 50-day average ($3.78) and -44.3% vs its 200-day average ($4.85).
- 52-week range $2.62–$7.82; today's close sits at 2% of that range, 65.5% below the 52-week high.
- That makes 8 straight losses.
TARA latest news & SEC filings
Every SEC filing by or about TARA in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Aug 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 11, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 11, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$21.67M (prior year -$14.96M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.36 (prior year -$0.35) (loss widened vs Jun 30, 2025)
Aug 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 7, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Shefferman Jesse sold 215,687 shares at $4.09 (≈$882.16K) on Jun 29, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jun 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Jun 29, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Things to know before you trade TARA
- Last results release: Aug 11, 2026 (8-K Item 2.02). Previous ones: May 13, 2026, Mar 10, 2026, Nov 10, 2025. Based on that rhythm, the next report is likely around Nov 10, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.39% (largest 9.5%). That is a volatile stock.
- Liquidity: about 1.75M shares (≈$4.20M) trade per day on average.
- 52-week position: $2.40 vs a range of $2.38–$7.82 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 3 sales; latest: Jesse Shefferman sold 215,687 shares on Jun 29, 2026.
- Latest filings: 10-Q Aug 11, 2026; 8-K Aug 11, 2026; 8-K Jun 29, 2026.
- Share count: 59.10M shares outstanding (Aug 7, 2026), +53.2% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
TARA market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 2.51 | 2.56 | 2.38 | 2.40 | 861.70K |
| Oct 14, 2026 | 2.60 | 2.66 | 2.47 | 2.48 | 701.40K |
| Oct 13, 2026 | 2.77 | 2.83 | 2.62 | 2.62 | 930.20K |
| Oct 12, 2026 | 2.75 | 2.79 | 2.70 | 2.77 | 1.08M |
| Oct 9, 2026 | 2.69 | 2.79 | 2.65 | 2.76 | 1.04M |
| Oct 8, 2026 | 2.59 | 2.69 | 2.52 | 2.65 | 1.22M |
| Oct 7, 2026 | 2.54 | 2.67 | 2.51 | 2.59 | 731.30K |
| Oct 6, 2026 | 2.63 | 2.70 | 2.53 | 2.56 | 803.50K |
| Oct 5, 2026 | 2.71 | 2.72 | 2.57 | 2.63 | 1.40M |
| Oct 2, 2026 | 2.81 | 2.95 | 2.62 | 2.70 | 1.91M |
| Oct 1, 2026 | 3.06 | 3.10 | 2.74 | 2.76 | 5.00M |
| Sep 30, 2026 | 3.23 | 3.30 | 2.98 | 3.05 | 8.82M |
| Sep 29, 2026 | 3.33 | 3.35 | 3.21 | 3.21 | 391.50K |
| Sep 28, 2026 | 3.27 | 3.39 | 3.19 | 3.25 | 431.10K |
| Sep 25, 2026 | 3.35 | 3.44 | 3.23 | 3.28 | 552.90K |
| Sep 24, 2026 | 3.54 | 3.55 | 3.32 | 3.35 | 661.90K |
| Sep 23, 2026 | 3.69 | 3.75 | 3.44 | 3.54 | 882.80K |
| Sep 22, 2026 | 3.55 | 3.88 | 3.55 | 3.68 | 2.89M |
| Sep 21, 2026 | 3.59 | 3.68 | 3.47 | 3.51 | 735.30K |
| Sep 18, 2026 | 3.69 | 3.72 | 3.45 | 3.55 | 3.95M |
About Protara Therapeutics
Protara Therapeutics (TARA) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in NEW YORK, NY. Fiscal year ends December 31. SEC CIK 1359931.
TARA board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Luke M Beshar | Director | Jun 16, 2026 |
| Barry P Flannelly | Director | Jun 16, 2026 |
| Roger Garceau | Director | Jun 16, 2026 |
| Jane Huang | Director | Jun 16, 2026 |
| Richard S Levy | Director | Jun 16, 2026 |
| Gregory Sargen | Director | Jun 16, 2026 |
| Jesse Shefferman | CEO and President | Jul 1, 2026 |
| Cynthia Smith | Director | Jun 16, 2026 |
| Michael Edward Solomon | Director | Jun 16, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| William Conkling | Chief Commercial Officer | Jun 3, 2026 |
| Patrick Fabbio | Chief Financial Officer | Jan 27, 2026 |
| Hannah Fry | VP, Controller | Jan 27, 2026 |
| Leonardo Viana Nicacio | Chief Medical Officer | Jan 21, 2026 |
| Jesse Shefferman | CEO and President | Jul 1, 2026 |
| Jacqueline Zummo | Chief R&D Officer | Apr 9, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 29, 2026 | Jesse Shefferman | Sale | 215,687 | $4.09 |
| Apr 8, 2026 | Jacqueline Zummo | Sale | 1,134 | $5.40 |
| Apr 1, 2026 | Jacqueline Zummo | Sale | 22,598 | $5.26 |
TARA financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-57.44M | -1.34 | $-56.37M |
| Dec 31, 2024 | — | $-44.60M | -2.17 | $-35.81M |
| Dec 31, 2023 | — | $-40.42M | -3.57 | $-37.56M |
| Dec 31, 2022 | — | $-65.95M | -5.86 | $-26.46M |
| Dec 31, 2021 | — | $-47.25M | -4.21 | $-34.50M |
Latest balance sheet: total assets $176.09M, total liabilities $14.78M, cash $17.08M (as of Jun 30, 2026).
TARA earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 11, 2026 | 8-K Item 2.02 (results) | $3.91 |
| May 13, 2026 | 8-K Item 2.02 (results) | $5.20 |
| Mar 10, 2026 | 8-K Item 2.02 (results) | $5.71 |
| Nov 10, 2025 | 8-K Item 2.02 (results) | $4.53 |
| Aug 11, 2025 | 8-K Item 2.02 (results) | $3.10 |
| May 8, 2025 | 8-K Item 2.02 (results) | $3.37 |
| Mar 5, 2025 | 8-K Item 2.02 (results) | $3.63 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $2.58 |
| Aug 6, 2024 | 8-K Item 2.02 (results) | — |
| May 2, 2024 | 8-K Item 2.02 (results) | — |
| Mar 13, 2024 | 8-K Item 2.02 (results) | — |
| Nov 3, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Biogen (BIIB)Halozyme Therapeutics (HALO)Revolution Medicines (RVMD)Recursion Pharmaceuticals (RXRX)ImmunityBio (IBRX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on TARA
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.